Novan Provides Update on SB414 Inflammatory Skin Disease Development Program

MORRISVILLE, N.C., May 15, 2018 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today is providing an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic indications: psoriasis and atopic dermatitis. As previously communicated on an investor webcast in October of 2017, the application of the Company’s underlying science, as applied to inflammatory-based dermatological indications, is an important part of the Company’s effort of exploring the full breadth of possibilities for its nitric oxide platform.